BTIG Research Initiates Coverage on Ascentage Pharma Group International (NASDAQ:AAPG)

Stock analysts at BTIG Research started coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a note issued to investors on Monday,Benzinga reports. The brokerage set a “buy” rating and a $50.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 57.58% from the company’s current price.

Separately, Piper Sandler started coverage on shares of Ascentage Pharma Group International in a report on Wednesday. They issued an “overweight” rating and a $48.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $49.00.

Ascentage Pharma Group International Stock Performance

Shares of NASDAQ:AAPG opened at $31.73 on Monday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53. The business has a 50-day simple moving average of $37.24 and a two-hundred day simple moving average of $35.50. Ascentage Pharma Group International has a fifty-two week low of $16.50 and a fifty-two week high of $48.45.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ascentage Pharma Group International during the third quarter valued at approximately $96,000. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth approximately $204,000. Chevy Chase Trust Holdings LLC bought a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at approximately $227,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the 2nd quarter valued at $391,000. Finally, Tema Etfs LLC bought a new stake in Ascentage Pharma Group International in the second quarter worth $610,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.